Ozempic Offers Unexpected Benefit: 15% Reduction in Bone Fractures, Major Study Reveals
A groundbreaking study unveiled at the annual ENDO 2026 meeting of the Endocrine Society in Chicago (June 13–16) has discovered an unexpected advantage of the highly successful weight-loss drug semaglutide (marketed under the brand names Ozempic, Wegovy, and Rybelsus): a significant increase in protection against bone fractures.
Researchers at the Stanford University Medical Center examined health records from nearly 60,000 adults with type 2 diabetes. They found that those using semaglutide experienced roughly 15% fewer bone fractures than those using other prevalent weight-loss medications — including dulaglutide, phentermine/topiramate, and bupropion/naltrexone — despite losing more weight overall.
The group using semaglutide reported only 794 fractures, compared to 1,045 in the control group. This is a significant discovery, as rapid weight loss has traditionally been linked with increased bone loss and fracture risk. Lead researcher Dr. Sun H. Kim, an associate professor at Stanford, stated that the findings “highlight potential bone-protective effects of semaglutide, decoupling the traditional clinical concern of weight-loss induced skeletal decline.”
While the researchers emphasize that further studies are required to validate these results, the implications for the millions of people currently using GLP-1 medications for diabetes and obesity management are substantial — and offer hope for long-term bone health.
Source: Endocrine Society — ENDO 2026 Press Release